NCT02436408View on ClinicalTrials.gov

VISmodegib for ORbital and Periocular Basal Cell Carcinoma

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 15, 2015

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Carcinoma, Basal Cell
Interventions
DRUG

Vismodegib

Trial Locations (1)

48109

University of Michigan Hospital, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT02436408 - VISmodegib for ORbital and Periocular Basal Cell Carcinoma | Biotech Hunter | Biotech Hunter